Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genetic Services Laboratory, |
RCV001817257 | SCV002067044 | uncertain significance | not specified | 2019-09-11 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002478051 | SCV002782442 | uncertain significance | Congenital amegakaryocytic thrombocytopenia; Primary myelofibrosis; Thrombocythemia 2 | 2022-03-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002541981 | SCV003295548 | uncertain significance | Congenital amegakaryocytic thrombocytopenia; Essential thrombocythemia | 2022-10-14 | criteria provided, single submitter | clinical testing | This sequence change replaces phenylalanine, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 105 of the MPL protein (p.Phe105Leu). This variant is present in population databases (rs145313814, gnomAD 0.04%). This variant has not been reported in the literature in individuals affected with MPL-related conditions. ClinVar contains an entry for this variant (Variation ID: 1336302). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt MPL protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Breakthrough Genomics, |
RCV004691442 | SCV005186635 | uncertain significance | not provided | criteria provided, single submitter | not provided |